Becton Dickinson & Co (MIL:1BDX)
€ 211.5 -2.1 (-0.98%) Market Cap: 60.75 Bil Enterprise Value: 77.74 Bil PE Ratio: 37.37 PB Ratio: 2.48 GF Score: 64/100

Becton Dickinson and Co at JPMorgan Healthcare Conference Transcript

Jan 11, 2022 / 07:15PM GMT
Robert Justin Marcus
JPMorgan Chase & Co, Research Division - Analyst

Good afternoon. Welcome back. I'm Robbie Marcus, med tech analyst at JPMorgan. Very happy to introduce our next company, Becton, Dickinson. We're going to start with a presentation by Tom Polen, the CEO; and then where we're going to bring in new CFO, Chris DelOrefice, for some question and answer afterwards. But Tom, I'll turn it over to you and join you in a little bit.

Thomas E. Polen
Becton, Dickinson and Company - President, CEO & Chairman

Okay. Thank you. And as always, it's a pleasure to be here, Robbie. Today, I'm going to cover several topics that we discussed in depth at our recent Investor Day, including BD's strategy, our meaningful progress and how we're very well positioned to deliver on our longer-term targets and drive value for all stakeholders now and consistently over the years ahead.

Go to Slide 2. Before I get started, I want to remind you that I will be making some forward-looking statements today. As such, I encourage you to read the disclaimer in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot